Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: The widening gap between mandated treatment guidelines and the real-world clinical arena

Kidney International Supplements

Volumn 6, Issue 1, 2016, Pages 20-28

  Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

big data analytics; cardiorenal comorbidities; chronic kidney disease; guideline recommendations for RAASi treatment; hyperkalemia; MR antagonism; prescribing patterns for RAASi; renin angiotensin inhibition

Indexed keywords

EID: 84964413642     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1016/j.kisu.2016.01.004     Document Type: Review

References (56)

1. C.P. Kovesdy Epidemiology of hyperkalemia: an update Kidney Int Suppl 6 2016 3 6
2. V.M. Campese, and G. Adenuga Electrophysiological and clinical consequences of hyperkalemia Kidney Int Suppl 6 2016 16 19
3. C.M. Ferrario, and W.B. Strawn Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease Am J Cardiol 98 2006 121 128
4. F. Shearer, C.C. Lang, and A.D. Struthers Renin-angiotensin-aldosterone system inhibitors in heart failure Clin Pharmacol Ther 94 2013 459 467
5. T.W. Hsu, J.S. Liu, S.C. Hung, and et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia JAMA Intern Med 174 2014 347 354
6. V.J. Dzau, E.M. Antman, H.R. Black, and et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation 114 2006 2850 2870
7. C.M. Ferrario New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism Hypertension 55 2010 445 452
8. 1 receptor blockade M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus, Inc. Philadelphia, PA 235 256
9. 1 receptor blockade M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus, Inc. Philadelphia, PA 215 222
10. 1 receptor antagonists as antihypertensive agents M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus, Inc. Philadelphia, PA 263 278
11. T.O. Morgan, C.D. Griffiths, and L.M.D. Delbridge Wall stress, angiotensin II, and left ventricular hypertrophy M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus, Inc. Philadelphia, PA 223 234
12. 1 angiotensin receptors in vascular remodeling in hypertension M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus; Inc. Philadelphia, PA 279 294
13. 1 receptor antagonists and the kidney M. Epstein, H.R. Brunner, Angiotensin II Receptor Antagonists 2000 Hanley & Belfus; Inc. Philadelphia, PA 295 316
14. D.A. Kasal, and E.L. Schiffrin Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities Int J Hypertens 2012 2012 829786 http://dx.doi.org/10.1155/2012/829786
15. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials [e-pub ahead of print]. Am J Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2015.10.011, accessed December 15, 2015.
16. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
17. Z.H. Israili Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 14 suppl 1 2000 S73 S86
18. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
19. J.J. McMurray, S. Adamopoulos, S.D. Anker, and et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
20. Kidney Disease Improving Global Outcomes (KDIGO) Working Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 2012 337 414
21. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 2013 1 150
22. Kidney Disease Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO clinical practice guideline for lipid management in chronic kidney disease Kidney Int Suppl 3 2013 259 305
23. L.A. Inker, B.C. Astor, C.H. Fox, and et al. KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD Am J Kidney Dis 63 2014 713 735
24. P.A. James, S. Oparil, B.L. Carter, and et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
25. S.J. Taler, R. Agarwal, G.L. Bakris, and et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD Am J Kidney Dis 62 2013 201 213
26. American Diabetes Association Cardiovascular disease and risk management Diabetes Care 39 suppl 2016 S60 S71
27. American Diabetes Association. Microvascular complications and foot care Diabetes Care 39 suppl 1 2016 S72 S80
28. G. Mancia, R. Fagard, K. Narkiewicz, and et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
29. K.B. Shah, K. Rao, R. Sawyer, and S.S. Gottlieb The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure J Am Coll Cardiol 46 2005 845 849
30. B. Bozkurt, M.D. Agoston, and A.A. Knowlton Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 2003 211 214
31. B. Pitt, F. Zannad, W.J. Remme, et al. for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
32. F. Zannad, J.J. McMurray, H. Krum, et al. for the EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
33. A.S. Go, G.M. Chertow, D. Fan, and et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
34. T. Yildirim, M. Arici, S. Piskinpasa, and et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren Fail 34 2012 1095 1099
35. B.F. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 2004 585 592
36. I. Lazich, and G.L. Bakris Prediction and management of hyperkalemia across the spectrum of chronic kidney disease Semin Nephrol 34 2014 333 339
37. M.A. Raebel Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Cardiovasc Ther 30 2012 e156 e166
38. P.A. Sarafidis, R. Blacklock, E. Wood, and et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic Clin J Am Soc Nephrol 7 2012 1234 1241
39. N. Jain, S. Kotla, B.B. Little, and et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 2012 1510 1513
40. C.P. Kovesdy Management of hyperkalaemia in chronic kidney disease Nat Rev Nephrol 10 2014 653 662
41. L.M. Einhorn, M. Zhan, V.D. Hsu, and et al. The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 169 2009 1156 1162
42. M.A. Perazella, and R.L. Mahnensmith Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis J Gen Intern Med 12 1997 646 656
43. M.R. Weir, and M. Rolfe Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors Clin J Am Soc Nephrol 5 2010 531 548
44. G.L. Bakris, B. Pitt, M.R. Weir, et al. The AMETHYST-DN Investigators Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial JAMA 314 2015 151 161
45. J.J. McMurray, M. Packer, A.S. Desai, et al. for the PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
46. M.J. Krantz, A.V. Ambardekar, L. Kaltenbach, et al. for the Get With the Guidelines Steering Committee and Hospitals Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines - Heart Failure) Am J Cardiol 107 2011 1818 1823
47. N.M. Albert, C.W. Yancy, L. Liang, and et al. Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
48. A.N. Rassi, M.A. Cavender, G.C. Fonarow, and et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction J Am Coll Cardiol 61 2013 35 40
49. A.P. Maggioni, S.D. Anker, U. Dahlström, et al. for the Heart Failure Association of the ESC Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry Eur J Heart Fail 15 2013 1173 1184
50. S. Shirazian, C.D. Grant, S. Mujeeb, and et al. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease Am J Med Sci 349 2015 510 515
51. M. Edner, L. Benson, U. Dahlström, and L.H. Lund Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study Eur Heart J 36 2015 2318 2326
52. M. Epstein, N.L. Reaven, S.E. Funk, and et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors Am J Manag Care 21 11 suppl 2015 S212 S220
53. M.R. Weir Current and future treatment options for managing hyperkalemia Kidney Int Suppl 6 2016 29 34
54. M.R. Weir, G.L. Bakris, D.A. Bushinsky, et al. OPAL-HK Investigators Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors N Engl J Med 372 2015 211 221
55. M. Kosiborod, H.S. Rasmussen, P. Lavin, and et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial JAMA 312 2014 2223 2233
56. D.K. Packham, H.S. Rasmussen, P.T. Lavin, and et al. Sodium zirconium cyclosilicate in hyperkalemia N Engl J Med 372 2015 222 231